A. Pavlov, A. Tsybulsky, I. Albitskiy, S. Garmash, A. Gerasimov, T. Isaev, D. Blinov
Evaluate the preliminary results of combined radiation therapy with high dose rate source (Ir-192) in the treatment of prostate cancer patients at high risk of progression.
From 2008 to 2010, 75 patients with a diagnosis of «prostate cancer» (PC) on combined treatment that included a high-dose brachytherapy Ir-192, followed by external beam radiation therapy (EBRT). All patients are at high risk of progression of the underlying disease.
During brachytherapy (BT), all patients received a single fraction of 10 Gy. The average value of the total dose was 44-46 Gy EBRT, 2 Gy per fraction.
All patients who participated in the study, conducted hormonal therapy for at least three months before the start of radiotherapy.
The mean duration of follow-up period for the entire group was 31.6 months. Indicator 3-year disease-free survival rate was 93.3%. The frequency of late radiation complications III degree (on a scale of RTOG) were as follows: lower urinary tract 5%. Complications IV degree was observed.
High-dose brachytherapy as boost combined with EBRT shows excellent clinical results, high rates of biochemical disease-free survival while maintaining quality of life at a high level.